- Home
- LMB vs NVCR Comparison
LMB vs NVCR Comparison
Compare LMB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- NVCR
- Stock Information
- Founded
- LMB 1901
- NVCR 2000
- Country
- LMB United States
- NVCR Switzerland
- Employees
- LMB N/A
- NVCR N/A
- Industry
- LMB Engineering & Construction
- NVCR Medical/Dental Instruments
- Sector
- LMB Consumer Discretionary
- NVCR Health Care
- Exchange
- LMB Nasdaq
- NVCR Nasdaq
- Market Cap
- LMB 1.6B
- NVCR 1.9B
- IPO Year
- LMB 2014
- NVCR 2015
- Fundamental
- Price
- LMB $149.20
- NVCR $17.71
- Analyst Decision
- LMB Strong Buy
- NVCR Buy
- Analyst Count
- LMB 3
- NVCR 6
- Target Price
- LMB $136.67
- NVCR $32.83
- AVG Volume (30 Days)
- LMB 202.6K
- NVCR 1.6M
- Earning Date
- LMB 08-05-2025
- NVCR 07-24-2025
- Dividend Yield
- LMB N/A
- NVCR N/A
- EPS Growth
- LMB 31.50
- NVCR N/A
- EPS
- LMB 2.78
- NVCR N/A
- Revenue
- LMB $532,913,000.00
- NVCR $621,711,000.00
- Revenue This Year
- LMB $20.01
- NVCR $5.56
- Revenue Next Year
- LMB $5.84
- NVCR $9.19
- P/E Ratio
- LMB $53.67
- NVCR N/A
- Revenue Growth
- LMB 3.62
- NVCR 18.27
- 52 Week Low
- LMB $48.17
- NVCR $14.17
- 52 Week High
- LMB $154.05
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- LMB 66.47
- NVCR 51.32
- Support Level
- LMB $134.74
- NVCR $17.53
- Resistance Level
- LMB $143.00
- NVCR $18.70
- Average True Range (ATR)
- LMB 5.60
- NVCR 0.72
- MACD
- LMB -0.30
- NVCR 0.09
- Stochastic Oscillator
- LMB 77.34
- NVCR 60.56
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.